SCHEMBL5451599

SCHEMBL5451599

CC(=O)n1cnc(CC(Nc2sc3c(c2C(N)=O)CCN(C)C3)C(=O)O)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 10/20 0.47
MEN1 O00255 6/20 0.47
ATM Q13315 1/20 0.46
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
MAPT P10636 3/20 0.43
ALDH1A1 P00352 2/20 0.43
KDM4E B2RXH2 2/20 0.43
GLA P06280 1/20 0.43
HPGD P15428 1/20 0.43
L3MBTL1 Q9Y468 3/20 0.42
PAX8 Q06710 1/20 0.42
ALOX15 P16050 2/20 0.41
TSHR P16473 2/20 0.41
HSD17B10 Q99714 1/20 0.41
PTPN2 P17706 1/20 0.40
PTPN1 P18031 1/20 0.40
POLB P06746 1/20 0.40
GAA P10253 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5460013 0.71 KMT2A (0.57) KMT2AMEN1ATMNPC1RAB9A
SCHEMBL5460054 0.70 KMT2A (0.63) KMT2AMEN1ATMNPC1RAB9A
SCHEMBL13151131 0.69 KMT2A (0.68) KMT2AMEN1ATMNPC1RAB9A
SCHEMBL16727751 0.67 CPB2 (0.48) MAPTALDH1A1KDM4EALOX15RECQL
SCHEMBL10077174 0.67 KMT2A (0.63) KMT2AMEN1ATMNPC1RAB9A
SCHEMBL5445189 0.66 ATM (0.49) KMT2AMEN1ATMNPC1RAB9A
SCHEMBL4437439 0.65 SLC7A5 (0.44) HSD17B10
SCHEMBL7001068 0.65 SLC7A5 (0.44) HSD17B10
SCHEMBL22392864 0.65 CPB2 (0.49)
SCHEMBL17044394 0.65 CPB2 (0.49)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 KMT2A 4785/4885MEN1 2891/4885ATM 2057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.